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Letters e149Dermatologists can have medications compounded
to use for patch testing (Fig 1).
To the best of our knowledge, there are no
reported cases of AGEP secondary to benzocaine
and only 2 previous reports of AGEP caused by
hydroxyzine.2,3 It may be that these common
medications have caused AGEP in the past that was
either unrecognized or not reported. Regardless,
it is important that dermatologists be aware of this
uncommon yet important adverse event.
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To the Editor:Cutaneous CD81 pseudolymphoma has
been reported in HIV-infected patients in association
with a reactive cutaneous infiltration of HIV-specific
CD81 cytotoxic T cells.1 The diagnostic features
include extensive plaquesor erythrodermamimicking
mycosis fungoides or Sezary syndrome, eosinophilia,
and a dermal CD81 cytotoxic T-lymphocyte infiltrate
without T-cell receptor rearrangement.2,3 Herein,
we describe an HIV-negative patient with psoriasisOpen access under CC BY-NC-ND license.in whom erythrodermic CD81 pseudolymphoma
developed after treatment with infliximab.
A 32-year-old white woman had a 3-year history
of biopsy-proven severe pustular psoriasis that
was unresponsive to topical corticosteroids and
narrowband ultraviolet B phototherapy. After
screening for infection, neoplasm, and autoimmu-
nity, all of which were negative, the patient was
given infliximab at a dose of 5 mg/kg at weeks 0, 2,
and 6, and then every 2 months. Her psoriasis
improved and at least a 50% reduction in body
surface area compared to baseline was observed
after 12 weeks. Eleven months later, severe
pruritic erythroderma associated with palmoplantar
hyperkeratosis and generalized lymphadenopathy
developed. Serologic and/or serum DNA detection
studies for Bartonella henselae, cytomegalovirus,
Epstein-Barr virus, HIV, and Toxoplasma gondii
were negative.
Two lesional skin biopsies showed a papillary
dermal lymphocytic infiltrate composed of small-
and medium-sized cells with mild epidermotropism.
Immunohistochemistry showed an overwhelming
predominance of CD21, CD31, CD51, CD71, and
CD81 T cells in the infiltrate. Scattered eosinophils
were also observed. Immunostaining of CD8 T cells
showed TiA-1 and granzyme B expression,
indicating their cytotoxic lineage. Clonal T-cell
receptor and immunoglobulin heavy chain gene
rearrangements were not detected. Direct immuno-
fluorescence was negative. Immunophenotyping
performed on lymph node and bone marrow biopsy
specimens showed a polyclonal CD8 T-cell infiltrate.
A blood cell count showed 1992 CD41 T cells/mm3,
3916 CD81 T cells/mm3, and 1160 eosinophils/mm3.
The CD4/CD8 ratio was 0.51, and there were no
circulating Sezary cells.
A diagnosis of erythrodermic CD81 pseudolym-
phoma was made, and infliximab was discontinued.
Despite infliximab withdrawal, the erythroderma
persisted, and the use of topical and systemic
corticosteroids followed by methotrexate was
unsuccessful (Fig 1). Because of worsening skin
symptoms associated with edema, chills, and overall
deterioration in the patient’s condition, treatment
with cyclosporine at doses up to 5 mg/kg/day was
initiated. The patient’s condition dramatically
improved and she was in complete clinical remission
within 4 months (Fig 2). The CD4/CD8 ratio
improved to 0.85.
As far as we know, in addition to our case, there
have been only 2 other reported cases of cutaneous
pseudolymphoma associated with anti-tumor
necrosis factor (TNF) therapy. One was induced by
adalimumab and subsequently the same eruption
Fig 1. Erythrodermic CD81 pseudolymphoma induced by
infliximab.
Fig 2. Erythrodermic CD81 pseudolymphoma resolved
after 4 months of cyclosporine.
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e150 Lettersresulted from infliximab treatment4; the other case
was induced by etanercept.5 However, unlike the
present case, erythroderma was not associated with
the reported cases, which could explain why the
pseudolymphomatous reaction resolved after
withdrawal of the drug in both cases. Moreover, in
the second case described, relapse did not occur
after the administration of another TNF inhibitor,
adalimumab. Because our patient developed
an erythrodermic reaction, treatment with TNF
inhibitors was halted. Cyclosporine was used as
rescue therapy and resulted in dramatic improve-
ment without any significant side effects.
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Aquagenic wrinkling: A unique facial
presentation
To the Editor: Aquagenic wrinkling of the palms
(AWP) is characterized by the formation of white
papules and plaques on the palms and fingers after
brief exposure to water. We extend the clinical
phenotype by describing a healthy adolescent girl
with aquagenic wrinkling (AW) of the face and
palms.
A 16-year-old girl presented with recurrent skin
changes of 18 months’ duration. She described the
abrupt appearance of superficial, whitish material on
her cheeks upon exposure to sweat and tap water,
which resolved within hours. No preceding medica-
tions or supplements were noted. Prior treatments
including topical antibiotics, corticosteroids, and
emollients were ineffective.
Application of tap water to the left cheek induced
off-white hyperkeratosis and wrinkling in less
than 3 minutes (Fig 1). Immersion of the right
hand in water for 4 minutes caused mild AW.
Testing for 97 common mutations in the cystic
